Lessons learned from 150 continuous-flow left ventricular assist devices: a single institutional 7 year experience

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Continuous-flow (CF) left ventricular assist devices (LVADs) are a standard treatment for advanced heart failure.
• Optimal medical therapy is often insufficient for end-stage heart failure patients.

Purpose of the Study:

• To review a single institution's seven-year experience with CF LVADs.
• To evaluate survival rates and complication incidence in patients receiving LVAD support.

Main Methods:

• Retrospective review of patients who received CF LVAD implantation over a seven-year period.
• Analysis of patient demographics, heart failure etiology, and clinical outcomes.
• Assessment of survival at multiple time points and common postoperative complications.

Main Results:

• Overall survival rates at 30 days, 6 months, 12 months, and 2 years were 93%, 89%, 84%, and 81%, respectively.
• Gastrointestinal bleeding (24%) and stroke (18%) were the most frequent complications.
• Right ventricular failure (18%) and driveline infection (9%) were also significant postoperative issues.

Conclusions:

• CF LVAD therapy provides excellent survival for both bridge-to-transplantation (BTT) and destination therapy (DT) patients.
• Reducing the incidence of complications such as gastrointestinal bleeding, stroke, and driveline infections is crucial for LVADs to become the gold standard for end-stage heart failure treatment.